ReviewFrontiers in pharmacology2021
Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Anti-inflammatory and antioxidant activity of astragalus polysaccharide in ulcerative colitis: A systematic review and meta-analysis of animal studies.Frontiers in pharmacology · 2022Pooled it
- Endophytic Fungal Metabolites as Modulators of Key Signaling Pathways in Chronic Diseases and Aging.Antibiotics (Basel, Switzerland) · 2026Review
- Efficacy of thePakistan journal of medical sciences · 2026Article
- Integrated Epithelial Models Reveal Anti-Inflammatory and Barrier Modulatory Properties of Ozoile in Inflammatory Bowel Disease.Antioxidants (Basel, Switzerland) · 2026Article
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- A Synergistic Approach with Doxycycline and Spirulina Extracts in DNBS-Induced Colitis: Enhancing Remission and Controlling Relapse.Journal of xenobiotics · 2025Article
- Probiotics in IBD: Evidence and Perspectives on Patient Health and Disease Management.International journal of molecular sciences · 2025Review
- A Mechanistic Approach to Replacing Antibiotics with Natural Products in the Treatment of Bacterial Diarrhea.Biomolecules · 2025Review
- Article
- The therapeutic mechanisms of quercetin on inflammatory diseases: an update.Inflammopharmacology · 2025Review
- Luteolin in Inflammatory Bowel Disease and Colorectal Cancer: A Disease Continuum Perspective.Current issues in molecular biology · 2025Review
- Potential of nutraceuticals in celiac disease.Tissue barriers · 2025Review
- Natural Product-based Therapies for Inflammatory Bowel Disease: Targeting Key Signaling Pathways.Mini reviews in medicinal chemistry · 2025Review
- The emerging role of honeysuckle flower in inflammatory bowel disease.Frontiers in nutrition · 2025Review
- Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury.Frontiers in pharmacology · 2025Review
- The Key Nutrients in the Mediterranean Diet and Their Effects in Inflammatory Bowel Disease: A Narrative Review.Nutrients · 2024Review
- Formulation, characterization, and evaluation of curcumin-loaded ginger-derived nanovesicles for anti-colitis activity.Journal of pharmaceutical analysis · 2024Article
- Layer by layer self-assembled hyaluronic acid nanoarmor for the treatment of ulcerative colitis.Journal of nanobiotechnology · 2024Article
- Biological Response of Treatment with Saffron Petal Extract on Cytokine-Induced Oxidative Stress and Inflammation in the Caco-2/Human Leukemia Monocytic Co-Culture Model.Antioxidants (Basel, Switzerland) · 2024Article
- Natural approaches for the management of ulcerative colitis: evidence of preclinical and clinical investigations.Natural products and bioprospecting · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) represents chronic recurrent intestinal inflammation resulting from various factors. Crohn's disease (CD) and ulcerative colitis (UC) have been identified as the two major types of IBD. Currently, most of the drugs for IBD used commonly in the clinic have adverse reactions, and only a few drugs present long-lasting treatment effects. Moreover, issues of drug resistance and disease recurrence are frequent and difficult to resolve. Together, these issues cause difficulties in treating patients with IBD. Therefore, the development of novel therapeutic agents for the prevention and treatment of IBD is of significance. In this context, research on natural compounds exhibiting anti-inflammatory activity could be a novel approach to developing effective therapeutic strategies for IBD. Phytochemicals such as astragalus polysaccharide (APS), quercetin, limonin, ginsenoside Rd, luteolin, kaempferol, and icariin are reported to be effective in IBD treatment. In brief, natural compounds with anti-inflammatory activities are considered important candidate drugs for IBD treatment. The present review discusses the potential of certain natural compounds and their synthetic derivatives in the prevention and treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.